0000000000215364

AUTHOR

Marta Ramírez-calvo

showing 3 related works from this author

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study

2020

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level, and they have been described as being associated with tumor prognosis. Here, miRNA profiling was planned to explore new molecular prognostic biomarkers in localized intestinal high-risk GIST. Paraffin tumor blocks of 14 and 86 patients were used in the discovery and expansion sets, respectively. GeneChip miRNA v3.0 was employed to identify the miRNAs differentially expressed between relapsed and non-relapsed patient samples, which were validated in the expansion set, by qRT-PCR. RT2 Profiler PCR Array was used for the screening of let-7e targets. Expression levels were co…

caspase-3Cancer Research<i>let-7e</i>Biologylcsh:RC254-282prognostic biomarkers:Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression [Medical Subject Headings]miR-550:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Cysteine Endopeptidases::Caspases::Caspases Effector::Caspase 3 [Medical Subject Headings]microRNAGene expressionmedicine:Chemicals and Drugs::Biological Factors::Biological Markers [Medical Subject Headings]Mirna profilingGastrointestinal stromal tumors:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Paraffin [Medical Subject Headings]GeneACVR1B:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Connective Tissue::Gastrointestinal Stromal Tumors [Medical Subject Headings]MicroARNsGiSTTumores del estroma gastrointestinalPronósticoMicroRNAlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosislet-7e:Chemicals and Drugs::Nucleic Acids Nucleotides and Nucleosides::Antisense Elements (Genetics)::RNA Antisense::MicroRNAs [Medical Subject Headings]BiomarcadoresOncologyPrognostic biomarkersCaspase-3<i>miR-550</i>Gene chip analysisCancer research:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]Target genesSarcomaGIST
researchProduct

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

2021

558 Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making in early-stage hormone receptor positive (HR+), epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Discordances in risk allocation between these platforms affect up to 30% of patients. This study aims to develop the MamaPred test to improve the diagnostic performance of recurrence risk in HR+/HER2- early-stage BC. Methods: A total of 606 HR+/HER2- early-stage BC previously tested with OT [n = 287; Low Risk (LR) = 165, Intermediate Risk (IR) = 103 and High Risk (HR) = 19] and MP (n = 3…

OncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.diseaseRecurrence riskBreast cancerOncologyMammaPrintInternal medicinemedicineRelapse riskStage (cooking)businessJournal of Clinical Oncology
researchProduct

Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS):…

2019

11067 Background: GEIS 30 was a phase II study showing moderate activity of pazopanib in well-differentiated/dedifferentiated LPS (cohort A:37 pts, Progression free Survival (PFS) at 12 weeks (w) 43.2%) and no activity in Myxoid/round cell LPS (cohort B: 15 pts, PFS at 12w 13.3%). The present study aims to identify tumor and plasma biomarkers that are differently expressed in long responders (LRs) PFS &gt; 24 w. Methods: Serum samples and paraffin-blocks at diagnosis were collected for 28 pts in cohort A and 11 in B. A total of 13 pts were LRs. Serum samples were obtained at baseline, after 3 w of treatment and at progression. A panel of 15 cytokines and growth factors were evaluated using…

OncologyCancer Researchmedicine.medical_specialtyMetastatic Liposarcomabusiness.industryPhases of clinical researchModerate activitymedicine.diseasePazopanibOncologyInternal medicineCohortmedicineIn patientSarcomaProgression-free survivalbusinessmedicine.drugJournal of Clinical Oncology
researchProduct